MAPT and Alzheimer disease: The finding of MCI participants with poor primacy performance exhibiting prodromal AD features is in agreement with prior evidence of poorer delayed primacy performance in cognitively intact individuals with smaller hippocampal volumes and increased CSF hyperphosphorylated tau levels [12], and AD-type SPE performance in asymptomatic participants with a familial history of AD [13].